PlumX Metrics
Embed PlumX Metrics

Pharmacogenetics of chemotherapy-induced nausea and vomiting

Pharmacogenomics, ISSN: 1744-8042, Vol: 16, Issue: 2, Page: 149-160
2015
  • 22
    Citations
  • 0
    Usage
  • 34
    Captures
  • 1
    Mentions
  • 885
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    22
  • Captures
    34
  • Mentions
    1
    • News Mentions
      1
      • 1
  • Social Media
    885
    • Shares, Likes & Comments
      885
      • Facebook
        885

Most Recent News

Risk Factors Associated with Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer Receiving Highly Emetogenic Chemotherapy: Individual Patient-Based Analysis of Three Prospective Antiemetic Trials

Introduction One of the key concerns of anticancer therapy is chemotherapy-induced nausea and vomiting (CINV), which leads to physical and psychological distress and impairs patients’

Review Description

Chemotherapy-induced nausea and vomiting (CINV) is associated with distressing adverse effects observed in patients during cytotoxic chemotherapy. One of the potential factors explaining suboptimal response to currently used antiemetics is variability in genes encoding enzymes and proteins that play a role in the action of antiemetic drugs. Pharmacogenomics studies of CINV are sparse and focus mainly on polymorphisms associated with serotonin receptor, drug metabolism and drug transport. Currently, the role of pharmacogenetics in mechanisms of CINV has not been fully unraveled, and it is premature to implement results of pharmacogenetic association studies of antiemetic drugs in clinical practice. More uniform studies, with genetic profiles and biomarkers relevant for the proposed target and transporter mechanisms, are needed.

Bibliographic Details

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know